The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1371-1378

  Romanini, Juliana ^a   Mielcke, Tânia R ^a   Leal, Paulo C ^b   Figueiredo, Cláudia P ^b   Calixto, João B ^b   Morrone, Fernanda B ^a   Batista Jr , Eraldo L ^a   Campos, Maria M ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Chemokines; CXCR2 receptors; Oral squamous cell carcinoma; SB225002; VEGF. Caspase 3

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; CASPASE 3; CHEMOKINE RECEPTOR CXCR2; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KERATINOCYTE; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; ORAL BIOPSY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TONGUE CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH NEOPLASMS; PHENYLUREA COMPOUNDS; RATS; RATS, INBRED F344; RECEPTORS, INTERLEUKIN-8B;

EID: 84866743571     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9701-x     Document Type: Article

References (37)

1. Al-Swiahb JN, Chen CH, Chuang HC, Fang FM, Tasi HT, Chien CY. (2010) Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 6:837-850
2. Chandu A, Smith ACH, Rogers SN. (2006) Health-related quality of life in oral cancer: a review. J Oral Maxillofac Surg 64:495-502
3. Massano J, Regateiro FS, Januário G, Ferreira A. (2006) Oral squamous cell carcinoma :review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:67-76
4. Rosenkilde MM, Schwartz TW. (2004) The chemokine system - a major regulator of angiogenesis in health and disease. APMIS 112:481-495
5. Charo IF, Ransohoff RM. (2006) The many roles of chemokines and chamokine receptors in inflammation. N Engl J Med 354:610-621
6. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. (2006) LR+CXC chemokines and their receptors. (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharm Ther 112:139-149
7. Strieter BMD, Mestasa J, Gompertsc B, Keane MP, Belperio JA. (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768-778
8. Matzer SP, Zombou J, Sarau HM, llinghoff MR, Ulrich Beuscher H. (2004) A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 209:225-233
9. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098
10. Kakinuma T, Hwang ST. (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 4:639-651
11. Rollins BJ. (2006) Inflammatory chemokines in cancer growth and progression. Eur J Cancer 42:760-767
12. Keeley EC, Mehrad B, Strieter RM. (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91-111
13. Bernardi A, Jacques-Silva MC, Delgado-Cañedo A, Lenz G, Battastini AMO. (2006) Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur J Pharmacol 532:214-222
14. Suzuki H, Mori M, Seto K, Shibata F, Nagahashi S, Kawaguchi C, Suzuki M, Matsui H, Watanabe K, Miura S, Ishii H. (2000) Rat CXC chemokine GRO/CINC-1 paradoxically stimulates the growth of gastric epithelial cells. Aliment Pharmacol Ther 14. (Suppl 1):94-100
15. Manjavachi MN, Quintão NL, Campos MM, Deschamps IK, Yunes RA, Nunes RJ, Leal PC, Calixto JB. (2010) The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. Eur J Pain 14:23-31
16. Hasegawa H, Kano M, Hoshi N, Watanabe K, Satoh E, Nakayama B, Suzuki T. (1998) An electrochemotherapy model for rat tongue carcinoma. J Oral Pathol Med 27:249-254
17. Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, Tohnai I, Ueda M, Sugiura Y. (2006) Mechanical Allodynia and Thermal Hyperalgesia Induced by Experimental Squamous Cell Carcinoma of the Lower Gingiva in Rats. J Pain 7:659-670
18. Anneroth G, Batsakis JG, Luna M. (1986) Malignancy grading of squamous cell carcinoma in the floor of the mouth related to clinical evaluation. Scand J Dent Res 94:347-358
19. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. (2006) A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 66:3071-3077
20. Kim HE, Krug MA, Han I, Ensley J, Yoo GH, Forman JD, Kim HR. (2000) Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cells. Clin Cancer Res 6:4142-4147
21. Deyrieux AF, Wilson VG. (2007) In vitro culture conditions to study keratinocyte differentiation using the HaCaT cell line. Cytotechnology 54:77-83
22. Watanabe H, Iwase M, Ohashi M, Nagumo M. (2002) Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38:670-679
23. Christofakis EP, Miyazaki H, Rubink DS, Yeudall WA. (2008) Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol 44:920-926
24. Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT. (2009) A Key Role for Early Growth Response-1 and Nuclear Factor-κB in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer. Mol Cancer Res 7:755-764
25. Liu Z, Yang L, Xu J, Zhang X, Wang B. (2011) Enhanced Expression and Clinical Significance of Chemokine Receptor CXCR2 in Hepatocellular Carcinoma. J Surg Res 166:241-246
26. Varney ML, Johansson SL, Singh RK. (2006) Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 125:209-216
27. Sharma B, Singh S, Varney ML, Singh RK. (2010) Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 14:435-442
28. Tse GM, Chan AWH, Yu KH, King AD, Wong KT, Chen GG, Tsang RKY, Chan ABW. (2007) Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. Ann Surg Oncol 14:3558-3565
29. Choi S, Myers JN. (2008) Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. J Dent Res 87:14
30. Sappayatosok K, Maneerat Y, Swasdison S, Viriyavejakul P, Dhanuthai K, Zwang J, Chaisri U. (2009) Expression of proinflammatory protein, iNOS, VEGF and COX-2 in Oral Squamous Cell Carcinoma. (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal 14:319-324
31. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25:201-209
32. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nör JE. (2005) Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 65:5063-5069
33. Petreaca ML, Yao M, Liu Y, DeFea K, Martins-Green M. (2007) Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8. (IL-8/CXCL8) Is Required for IL-8/CXCL8- induced Endothelial Permeability. Mol Biol Cell 18:5014-5023
34. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16:3875-3886
35. Zhang HY, Meng X, Du ZX, Fang CQ, Liu GL, Wang HQ, Deng WW. (2009) Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin Exp Med 9:207-213
36. Sitorus RS, Gumay S, van der Valk P. (2009) The apoptotic paradox in retinoblastoma. Ann N Y Acad Sci 1171:77-86
37. Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW. (2009) Clinical significance of stromal apoptosis in colorectal cancer. Br J Cancer 101:765-773